Cancer clinical trials in the region Auvergne-Rhône-Alpes

316 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 1 / Phase 2 Lymphoma #NCT04623541 #2023-504828-25-00

[EPCORE™ CLL-1] Étude d'innocuité et d'efficacité de l'EPCORITAMAB chez des sujets atteints de leucémie lymphoïde chronique récidivante/réfractaire et du syndrome de Richter

B cell lymphoma Lymphocytic lymphoma CD20 None 1 2 3 or more

Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant

Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)

Genmab

Phase 1 / Phase 2 Endometrial cancer #NCT04008797 #2023-510275-64-00

Étude de l'E7386 en association avec d'autres médicaments anticancéreux chez des participants atteints d'une tumeur solide

Locally Advanced Metastatic 1 2 Immunotherapy Chemotherapy

Systemic Treatment-Naive

Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Jean Perrin (Clermont Ferrand )

Eisai Inc.

Phase 1 / Phase 2 #NCT05118789

[ARROS-1] Etude du NVL-520 chez des patients atteints d'un cancer du poumon non à petites cellules avancé et d'autres tumeurs solides hébergeant un réarrangement de ROS1 - Cohorte 2e

Locally Advanced Metastatic ROS-1 1

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Nuvalent Inc.

Phase 1 / Phase 2 Prostate cancer #NCT04585750 #2023-504251-27-00

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Metastatic Castration-resistant TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive